Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score-matching studies
Minmin Li MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Graduate College, Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorBin Zhang PhD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Graduate College, Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorQiuying Chen MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorLu Zhang PhD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorXiaokai Mo MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorZhuozhi Chen MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorZhe Jin MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorLuyan Chen MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorJingjing You MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorCorresponding Author
Shuixing Zhang PhD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Correspondence
Shuixing Zhang, MD, PhD, The First Affiliated Hospital of Jinan University, No. 613 Huangpu West Road, Tianhe District, Guangzhou, Guangdong 510627, China.
Email: [email protected]
Search for more papers by this authorMinmin Li MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Graduate College, Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorBin Zhang PhD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Graduate College, Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorQiuying Chen MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorLu Zhang PhD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorXiaokai Mo MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorZhuozhi Chen MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorZhe Jin MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorLuyan Chen MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorJingjing You MD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Search for more papers by this authorCorresponding Author
Shuixing Zhang PhD
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Correspondence
Shuixing Zhang, MD, PhD, The First Affiliated Hospital of Jinan University, No. 613 Huangpu West Road, Tianhe District, Guangzhou, Guangdong 510627, China.
Email: [email protected]
Search for more papers by this authorFunding information: China Postdoctoral Science Foundation, Grant/Award Number: 2016M600145; National Natural Science Foundation of China, Grant/Award Numbers: 81571664, 81801665, 81871323; National Natural Science Foundation of Guangdong Province, Grant/Award Number: 2018B030311024; Scientific Research General Project of Guangzhou Science Technology and Innovation Commission, Grant/Award Number: 201707010328
Abstract
Objective
To determine the benefits of adding induction chemotherapy (IC) and adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) for nasopharyngeal carcinoma (NPC) based on propensity score-matching (PSM) studies.
Methods
Eligible PSM studies were searched in the PubMed, Web of Science, and Embase databases from inception to September 1, 2020. The primary endpoints included overall survival (OS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS).
Results
A total of 14 trials consisting of 4086 participants were included. Significant benefits were observed between IC + CCRT and CCRT for OS (hazard ratio [HR], 0.76; 95% confidence interval [CI]: 0.64–0.91) and DMFS (HR, 0.77; 95% CI: 0.64–0.94) with the exception of LRFS (HR, 1.14; 95% CI: 0.90–1.43). However, CCRT + AC did not achieve significant improvements.
Conclusions
IC with CCRT yields significant survival benefits in terms of OS and DMFS, whereas CCRT with AC fails to achieve any additional benefit in all endpoints.
CONFLICT OF INTEREST
The authors declared no potential conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| hed26664-sup-0001-supinfo.docxWord 2007 document , 14.5 KB | Appendix S1: Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Wei WI, Sham JST. Nasopharyngeal carcinoma. Lancet. 2005; 365(9476): 2041-2054.
- 2Lee AWM, Lin JC, Ng WT. Current Management of Nasopharyngeal Cancer. Semin Radiat Oncol. 2012; 22(3): 233-244.
- 3Chan ATC, Gregoire V, Lefebvre JL, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23: 83-85.
- 4Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009; 73(5): 1326-1334.
- 5Baujat B, Audry W, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006; 64(1): 47-56.
- 6Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011; 80(3): 661-668.
- 7Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014; 110(3): 398-403.
- 8OuYang PY, Xie C, Mao YP, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013; 24(8): 2136-2146.
- 9You R, Cao YS, Huang PY, et al. The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two/three-dimensional radiotherapy to intensity-modulated radiotherapy: a network meta-analysis. Theranostics. 2017; 7(19): 4825-4835.
- 10Zhang B, Li MM, Chen WH, et al. Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. JAMA Netw Open. 2019; 2:e1913619.
- 11Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014; 33(7): 1242-1258.
- 12Dahabreh IJ, Sheldrick RC, Paulus JK, et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J. 2012; 33(15): 1893-1901.
- 13Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001; 286(7): 821-830.
- 14Wu LR, Jiang XS, Song X, et al. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis. Oncotarget. 2017; 8(45): 79953-79963.
- 15Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16.
- 16Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17(24): 2815-2834.
10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 17Ji XM, Xie CH, Hu DS, Fan X, Zhou YJ, Zheng YJ. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma. PLoS One. 2013; 8(2):e56208. https://doi.org/10.1371/journal.pone.0056208.
- 18Chen YP, Zhang WN, Tang LL, et al. Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone. BMC Cancer. 2015; 15: 930.
- 19Li WF, Li YQ, Chen L, et al. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. BMC Cancer. 2015; 15(1):810. https://doi.org/10.1186/s12885-015-1768-x.
- 20Zhang LN, Gao YH, Lan XW, Tang J, Ouyang PY, Xie FY. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a large scale propensity-matched study. Oral Oncol. 2015; 51(10): 950-956.
- 21Chen KH, Zhu XD, Li L, et al. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma. Oncotarget. 2016; 7(42): 69041-69050.
- 22Dong YY, Xiang C, Lu JX, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma A matched-pair multicenter analysis of outcomes. Strahlenther Onkol. 2016; 192(6): 394-402.
- 23Guo SS, Tang LQ, Chen QY, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA >/=4000 copies/ml: a matched study. Oncotarget. 2016; 7(20): 29739-29748.
- 24Song JH, Wu HG, Keam BS, et al. The role of neoadjuvant chemotherapy in the treatment of nasopharyngeal carcinoma: a multi-institutional retrospective study (KROG 11-06) using propensity score matching analysis. Cancer Res Treat. 2016; 48(3): 917-927.
- 25Lan XW, Xiao Y, Zou XB, Zhang XM, OuYang PY, Xie FY. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. Onco Targets Ther. 2017; 10: 3853-3860.
- 26Pan XB, Huang ST, Chen KH, Zhu XD. Chemotherapy use and survival in stage II nasopharyngeal carcinoma. Oncotarget. 2017; 8(60): 102573-102580.
- 27Peng H, Chen L, Zhang J, et al. Induction chemotherapy improved Long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy. J Cancer. 2017; 8(3): 371-377.
- 28Wang CL, Tang X, Wang JJ, Song J, Xu YH. Induction chemotherapy plus concurrent chemoradiotherapy vs concurrent chemoradiotherapy in elderly patients with advanced nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 2017; 157(2): 233-238.
- 29Zhong QL, Zhu XD, Li L, et al. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma. Oncotarget. 2017; 8(24): 39683-39694.
- 30Chen XL, Zhu XD, Liang ZG, et al. Long-term outcomes of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (CCRT) vs CCRT alone for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy using propensity score matching method. Onco Targets Ther. 2017; 10: 2909-2921.
- 31Chen YP, Guo R, Liu N, et al. Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis of randomized controlled trials. J Cancer. 2015; 6(9): 883-892.
- 32Song Y, Wang W, Tao G, Zhou X. Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma-A time-to-event meta-analysis. Oral Oncol. 2015; 51(8): 764-769.
- 33Yan M, Kumachev A, Siu LL, Chan KKW. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis. Eur J Cancer. 2015; 51(12): 1570-1579.
- 34Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res. 2018; 24(8): 1824-1833.
- 35Tan TH, Soon YY, Cheo T, et al. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: a systematic review and meta-analysis. Radiother Oncol. 2018; 129(1): 10-17.
- 36Yuan C, Xu XH, Luo SW, et al. Which neoadjuvant chemotherapy regimen should be recommended for patients with advanced nasopharyngeal carcinoma?: a network meta-analysis. Medicine (Baltimore). 2018; 97(34):e11978.
- 37Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019; 381(12): 1124-1135.
- 38Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral Oncol. 2015; 51(11): 1041-1046.
- 39Liang ZG, Zhu XD, Zhou ZR, Qu S, Du YU, Jiang YM. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 patients from 5 randomized controlled trials. Asian Pac J Cancer Prev. 2012; 13(11): 5747-5752.
- 40Chen YP, Wang ZX, Chen L, et al. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015; 26(1): 205-211.
- 41Lee AWM, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005; 23(28): 6966-6975.
- 42Lee AWM, Tung SY, Chan ATC, et al. Preliminary results of a randomized study (NPC-9902 trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66(1): 142-151.
- 43Lee A, Tung SY, Chan ATC, et al. Final report of NPC-9902 trial on therapeutic gain and late toxicities by concurrent-adjuvant chemotherapy and/or accelerated fractionation for T3-4N0-1M0 nasopharyngeal carcinoma. Eur J Cancer. 2009; 7(2–3): 22.
- 44Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010; 102(15): 1188-1198.
- 45Hui EP, Ma BBY, Chan ATC. The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma. Curr Opin Oncol. 2020; 32(3): 187-195.
- 46Benedetto U, Gaudino M, Caputo M, et al. Right internal thoracic artery versus radial artery as the second best arterial conduit: insights from a meta-analysis of propensity-matched data on long-term survival. J Thorac Cardiovasc Surg. 2016; 152: 1083-1091.e15.
Citing Literature
